NASDAQ · RNAZ
Healthcare · Biotechnology
$2.87
Down-$0.10 (-3.37%)
Updated Aug 24, 2026, 2:15 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
RNAZ closed at $2.87 after 20 trading sessions, down 47.34% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.90 | $3.00 | $2.87 | $2.87 | 42.18K |
| Aug 20, 2026 | $3.121 | $3.28 | $2.87 | $2.97 | 45.69K |
| Aug 19, 2026 | $3.27 | $3.4899 | $3.03 | $3.21 | 76.13K |
| Aug 18, 2026 | $3.00 | $3.37 | $3.00 | $3.24 | 22.06K |
| Aug 17, 2026 | $3.36 | $3.4978 | $2.9432 | $3.16 | 81.26K |
| Aug 14, 2026 | $3.50 | $3.70 | $3.21 | $3.28 | 41.01K |
| Aug 13, 2026 | $3.42 | $3.50 | $3.30 | $3.48 | 23.98K |
| Aug 12, 2026 | $3.40 | $3.61 | $3.32 | $3.37 | 21.58K |
| Aug 11, 2026 | $3.90 | $3.9799 | $3.43 | $3.43 | 24.12K |
| Aug 10, 2026 | $3.91 | $4.26 | $3.88 | $3.88 | 20.14K |
| Aug 7, 2026 | $4.00 | $4.3099 | $3.96 | $3.96 | 28.59K |
| Aug 6, 2026 | $4.30 | $4.30 | $3.99 | $4.27 | 13.39K |
| Aug 5, 2026 | $4.54 | $4.54 | $4.25 | $4.25 | 8.37K |
| Aug 4, 2026 | $4.38 | $4.72 | $4.38 | $4.45 | 14.48K |
| Aug 3, 2026 | $4.5207 | $4.62 | $4.22 | $4.22 | 10.71K |
| Jul 31, 2026 | $5.13 | $5.3699 | $4.47 | $4.56 | 30.26K |
| Jul 30, 2026 | $5.06 | $5.505 | $5.0014 | $5.25 | 10.35K |
| Jul 29, 2026 | $4.85 | $5.3136 | $4.80 | $4.96 | 5.23K |
| Jul 28, 2026 | $5.80 | $6.00 | $4.5001 | $5.00 | 42.48K |
| Jul 27, 2026 | $5.89 | $6.125 | $5.40 | $5.45 | 24K |
The latest Smart Investors Daily articles mentioning RNAZ.
RNAZ research
Company profile and research snapshot.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 6, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 3, 2026
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/
Benzinga · Feb 5, 2026
Benzinga · Feb 5, 2026
As part of the PRE-I-SPY platform, the TTX-MC138 Phase 2a dose-expansion portion of the trial will enroll up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and have
Benzinga · Feb 5, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RNAZ.
